Recursion Pharmaceuticals

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Cyclica Inc. is a Toronto-based company that specializes in enhancing the drug discovery process through its integrated cloud-based platform, which leverages artificial intelligence and biophysics. The company offers two main technologies: Ligand Design, which generates novel molecules and filters them based on various properties, and Ligand Express, a platform that screens small-molecule drugs against structurally-characterized protein repositories to assess poly-pharmacological profiles. This innovative approach allows pharmaceutical scientists to identify potential ligand-protein interactions, prioritize lead candidates, and explore opportunities for drug repurposing while also understanding potential adverse effects. Cyclica has established a strategic partnership with AUM Biosciences and has been operational since its incorporation in 2010.

InVivo AI, founded in 2017 and based in Montreal, Canada, specializes in utilizing artificial intelligence to enhance pharmaceutical research and development, particularly in the area of preclinical toxicology. The company aims to streamline the drug discovery process by implementing advanced AI methods for molecular representation and de novo design, which allows for the creation of novel chemical compounds that can address complex biological challenges. Through its innovative platform, InVivo AI is positioned to significantly improve the efficiency and effectiveness of drug design, paving the way for breakthroughs in pharmaceutical science.

Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Fully accredited by AAALAC International, Vium has received commendation for its commitment to the principles of humane animal research. The company's platform, known as Digital Vivarium and Vium Cloud, integrates advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively capture and analyze physiological metrics and behaviors. This innovative approach provides researchers across biotechnology, pharmaceutical, and academic sectors with accurate data that facilitates better decision-making regarding which compounds to advance to clinical trials. Founded in 2013 and headquartered in San Mateo, California, Vium aims to accelerate the preclinical drug discovery and development pipeline while ensuring ethical standards in research practices.